Antimicrobial activity of a phage mixture and a lactic acid bacterium against <i>staphylococcus aureus</i> from bovine mastitis by Titze, Isabel & Krömker, Volker
u n i ve r s i t y  o f  co pe n h ag e n  
Antimicrobial activity of a phage mixture and a lactic acid bacterium against
staphylococcus aureus from bovine mastitis
Titze, Isabel; Krömker, Volker
Published in:
Veterinary Sciences
DOI:
10.3390/vetsci7010031
Publication date:
2020
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Titze, I., & Krömker, V. (2020). Antimicrobial activity of a phage mixture and a lactic acid bacterium against
staphylococcus aureus from bovine mastitis. Veterinary Sciences, 7(1), [31].
https://doi.org/10.3390/vetsci7010031
Download date: 10. sep.. 2020
veterinary
sciences
Article
Antimicrobial Activity of a Phage Mixture and
a Lactic Acid Bacterium against Staphylococcus aureus
from Bovine Mastitis
Isabel Titze 1 and Volker Krömker 1,2,*
1 Department of Bioprocess Engineering and Microbiology, Hannover University of Applied Sciences and
Arts, D-30453 Hannover, Germany; isabel.titze@tiho-hannover.de
2 University of Copenhagen, Faculty of Health and Medical Sciences, Department of Veterinary and Animal
Sciences, Section for Production, Nutrition and Health, Gronnegardsvej 2,
DK-1870 Frederiksberg C, Denmark
* Correspondence: Volker.kroemker@sund.ku.dk
Received: 18 February 2020; Accepted: 4 March 2020; Published: 6 March 2020


Abstract: The antimicrobial activity of a phage mixture and a lactic acid bacterium against Staphylococcus
aureus isolates from bovine origin was investigated in vitro with regard to possible applications in
the therapy of udder inflammation (mastitis) caused by bacterial infections. The S. aureus isolates
used for inoculation derived from quarter foremilk samples of mastitis cases. For the examination of
the antimicrobial activity, the reduction of the S. aureus germ density was determined [log10 cfu/mL].
The phage mixture consisted of the three obligatory lytic and S. aureus-specific phages STA1.ST29,
EB1.ST11 and EB1.ST27 (1:1:1). The selected Lactobacillus plantarum strain with proven antimicrobial
properties and the phage mixture were tested against S. aureus in milk, both alone and in combination.
The application of the lactic acid bacterium showed only a low reduction ability for a 24 h incubation
period. The bacteriophage mixture as well as its combination with the lactic acid bacterium showed
high antimicrobial activity against S. aureus for a 24 h incubation period at 37 ◦C, with only the phage
mixture showing significance.
Keywords: Staphylococcus aureus; bacteriophage mixture; phage therapy; lytic phage; lactic acid
bacterium; dairy; bovine mastitis
1. Introduction
The therapy of intramammary infections (IMIs) in conventional dairy farming involves the use of
antimicrobial agents for treatment during lactation and for selective drying off [1,2]. A targeted use of
antibiotics is necessary to ensure the health and well-being of animals and to achieve a high level of food
safety. Nevertheless, bacterial resistance against antimicrobial agents in human as well as veterinary
medicine and increasing public concern about the usage of antibiotics in food-producing animals make it
necessary to further reduce their application [3–5].
Staphylococcus (S.) aureus, a Gram-positive, catalase-positive and coagulase-positive bacterium,
represents one of the most important mastitis pathogens [6,7]. Although environment-associated pathogens
have become increasingly important, there are still significant aspects to consider, such as the remediation of
S. aureus at the herd level, which still represents a long-term and labor-intensive process. As a cow-associated
major pathogen, S. aureus is spread between animals, especially during the milking process [7–9]. Moreover,
characteristics such as low cure rates and a long persistence in the mammary gland make it a difficult-to-treat
udder pathogen whose sanitation requires additional hygiene and management efforts [4,7,10]. Control
programs covering aspects of milking hygiene, separation of infected animals and therapeutic measures
are therefore particularly important [11,12]. Dufour et al. used multilevel regression models to investigate
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the risk factors associated with prevalence, incidence during lactation and elimination of S. aureus-induced
bovine IMI [13]. Key factors related to low prevalence in the herd include a low incidence as the most
important factor on herd level and a high elimination rate of S. aureus. The incidence of S. aureus IMI was
mainly associated with milking procedures (hygiene measures: wearing gloves, disinfection of teats before
milking; good condition of teat ends). These factors are simultaneously associated with the reduction of
the prevalence and the elimination of S. aureus [13].
The pathogenicity factors enable S. aureus to perform encapsulation, intracellular occurrence,
adhesion to epithelial cells and biofilm formation [14]. This often leads to subclinical or chronic
inflammation of the bovine mammary gland, impedes the effect of an antibiotic treatment and might
be the cause of insufficient cure rates for an antibiotic treatment during lactation [7,15]. Therefore,
antimicrobial alternatives are of particular interest to increase the bacteriological cure (BC) rates during
lactation while significantly reducing the application of antibiotics [16].
The use of bacteriophages (phages) for the treatment of bacterial infections (bacteriophage therapy)
represents such an alternative approach. Several studies in animal models have already investigated
bacteriophages, with promising results regarding a therapeutic use [17–20]. Phages hold various
advantages over conventional antibiotic agents, as they are very host specific and thus protect the
physiological bacterial flora [21,22]. Furthermore, new phages can be isolated within a comparatively
short time. This advantage, the possibility of combining different phages in the form of a bacteriophage
mixture, as well as the possibility to combine phages and antibiotics reduce the risk of a resistance
development against single phages [23–25]. Various studies indicate a prolonged antibiotic therapy of
S. aureus-induced intramammary infections (IMIs) to improve bacteriological cure rates, resulting in an
increased use of antimicrobial agents [26–28]. For this reason, alternative treatment methods such as
phage therapy could be particularly useful to reduce the amount of antibiotics administered.
Lactic acid bacteria (LAB) are a heterogeneous group of Gram-positive, catalase-negative and facultative
anaerobic microorganisms which are summarized due to their specific kind of metabolism [29,30]. LAB also
possess antimicrobial properties resulting from the colonization of epithelia, the competition for nutrients
and the production of organic acids such as lactic acid, free fatty acids as well as hydrogen peroxide,
diacetyl, bacteriocins or bacteriocin-like substances [31–33]. Furthermore, LAB are able to modulate the
host’s immune system [34]. The term “probiotic”, which is closely associated with LAB and bifidobacteria,
is used in the sense of “health promoting” and “probiotics” are, by definition, living microorganisms with
a consumer health benefit when properly administered [29,31,35]. Several in vitro and in vivo studies
on the antimicrobial activity of LAB against S. aureus were published [36–38]. A number of studies on
the use of LAB for the therapy of bovine udder infections have already been carried out, with promising
results [39–41]. Crispie et al. (2004) even described the use of a lacticin produced by the probiotic Lactococcus
lactis DPC 3147 as effective as a conventional antibiotic treatment for dry cow therapy [42].
Lactobacillus plantarum is a facultative heterofermentative LAB, which is mostly isolated from dairy
products, sewage and from human or clinical origin [30,43]. Lb. plantarum strains are known for their
probiotic properties, including the formation of a specific bacteriocin, called plantaricin [37,44–46].
The aim of the present study was the in vitro investigation of the antimicrobial activity for the
combination of an obligately lytic bacteriophage mixture (PM) and the Lb. plantarum strain 118/37
against S. aureus isolates from mastitis cases. The Lb. plantarum strain 118/37 has been extensively
tested in previous examinations and has proven its antimicrobial activity against S. aureus [47].
The examinations were conducted regarding a combined application in vivo for the therapy of S. aureus
mastitis during lactation.
2. Materials and Methods
2.1. S. aureus Strains and Growth Conditions
The S. aureus isolates 7142 and 10614 used for inoculation of ultra-high temperature (UHT)
milk were isolated from two different dairy farms in Germany and provided by the Department
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of Bioprocess Engineering and Microbiology, University of Applied Sciences and Arts Hannover
(Germany). They were obtained from quarter foremilk samples of mastitis cases and were tested as
coagulase-positive as well as screened nuc gene-positive. To confirm these results for the present
study, species affiliation was performed using matrix-assisted laser desorption time-of-flight-mass
spectrometry (MALDI-TOF), resulting in S. aureus for both isolates. The isolates were stored at −80 ◦C
with addition of 20 % glycerin after a 24 h culture in brain heart broth and plated on esculin blood agar
(Oxoid Deutschland GmbH, Wesel, Germany) (24 h at 37 ◦C) before use.
The S. aureus strains ST11, ST27 and ST29, isolated and provided by the Phage Technology Center
(PTC) GmbH, Bönen (Germany), were used for routine phage propagation (Table 1). The strains ST11 and
ST27 originated from mastitis cases. The phage propagation strains were stored at −80 ◦C with addition
of 20 % glycerin and plated on esculin blood agar (Oxoid Deutschland GmbH, Wesel, Germany) before
use. Luria–Bertani (LB) broth (trypton/pepton form casein: 1 g/100 mL; yeast extract, micro-granulated:
0.5 g/100 mL; sodium chloride (NaCl): 0.5 g/100 mL; Carl Roth GmbH & Co. KG, Karlsruhe, Germany)
was used for bacterial growth in suspension and for phage plaque assay. LB broth was supplemented
with agar (Agar Agar Bioscience; Carl Roth GmbH & Co. KG, Karlsruhe, Germany) at concentrations of
1.5 % for bottom and 0.5 % for top agar and sterile dextrose was added at 1.1 % to the top agar before
use. Baird–Parker agar (Carl Roth GmbH & Co. KG, Karlsruhe, Germany) supplemented with egg yolk
tellurite-emulsion (Carl Roth GmbH & Co. KG, Karlsruhe, Germany) was used for differential counting
of S. aureus germ density.
Table 1. Bacteriophages and Staphylococcus aureus propagation strains.
Phage Family;Relationship Phage Origin
Propagation Strain
(S. aureus) Strain Origin
STA1.ST29 Myovirus;related to phage K sewage water ST29 human isolate
EB1.ST11 Podovirus;related to phage PSa3 pig manure ST11
mastitis milk
sample
EB1.ST27 Podovirus;related to phage PSa3 pig manure ST27
mastitis milk
sample
All phages were isolated and sequenced by PTC GmbH, Bönen, Germany, and are available upon request.
2.2. Lactic Acid Bacterium and Growth Conditions
The lactic acid bacterium (LAB) 118/37 identified as Lactobacillus (Lb.) plantarum is an isolate from
bovine milk and was provided by the Department of Bioprocess Engineering and Microbiology of the
University of Applied Sciences and Arts Hannover (Germany). It has been isolated and described
in a research project, tested for its antimicrobial properties and patented. Details can be found at
Diepers et al. (2017) [47]. The LAB was stored at −80 ◦C with addition of 20 % glycerin after a 24 h
culture in de Man, Rogosa and Sharpe (MRS) broth (Merck, Darmstadt, Germany). It was cultured
twice in MRS broth (37 ◦C, 24 h, anaerobically) and simultaneously plated on MRS-agar (Merck,
Darmstadt, Germany) for optical detection of purity before every use. Species identification based on
microbiological identification for Gram-positive, catalase-negative, oxidase-negative (Bactident Oxidase;
Merck, Darmstadt, Deutschland), fermentative (OF basal medium with addition of D(+)-glucose
monohydrate; Merck, Darmstadt, Deutschland), H2S-negative, immotile rods. Further biochemical
and genetic species identification was performed by Diepers et al. (2017) and based on analytic profile
index (API) assay and the detection of 16SrDNA sequence according to Kwon et al. (2004) [47,48].
To confirm these results for the present study, species affiliation was performed additionally using
MALDI-TOF, resulting in Lb. plantarum for the LAB strain 118/37.
LAB 118/37 was chosen for the present examinations according to safety requirements (no resistance
coding genes) and properties such as the proven antimicrobial activity against S. aureus ATCC 12600
and the adhesion to teat canal epithelial cells in vitro [47].
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2.3. Bacteriophages
Bacteriophages STA1.ST29, EB1.ST11 and EB1.ST27 were isolated and provided by PTC GmbH,
Bönen (Germany). These lytic, sequenced phages belong to the order of Caudovirales and the families
of Myoviridae (STA1) and Podoviridae (EB1) (Table 1). Phage STA1 is an isolate of a wastewater facility
and is closely related to Phage K, which was isolated and characterized by O’Flaherty in 2004 [49].
Phage EB1 is an isolate from pig manure and is closely related to the phage PSa3, which was isolated
and characterized by Kraushaar et al. in 2013 [50]. The genetically distinct phages were grown on
different host strains (ST29; ST11 or ST27), which might have led to epigenetic modifications [51] that
resulted in a different host range in previous examinations [52].
A bacteriophage mixture (PM) was prepared to enlarge the host range for the examination in
UHT milk and with regard to an in vivo use and to decrease the risk of a resistance development
against single phages [25]. It contained phages STA1.ST29, EB1.ST11 and EB1.ST27 in equal quantities
and a final concentration of 7.4 × 109 pfu/mL. The phages were selected according to previously
examined criteria including a broad host range against S. aureus isolates from mastitis cases, good
propagation properties and adequate storage stabilities [52]. All phages of the mixture showed lytic
activity against the S. aureus isolates 7142 and 10614 in the plaque assay and the phage mixture (PM)
showed antimicrobial activity against the S. aureus isolates in pasteurized and raw milk in previous
examinations [52].
2.4. Bacteriophage Propagation
For phage propagation, LB broth was inoculated with 1 % of an overnight culture of the respective
S. aureus strain (ST11, ST27 or ST29). The optical density at 600 nm (OD600) was determined by a photometer
(SPEKOL®1500, Analytik Jena AG, Jena, Germany) every 30 min and one percent of a phage stock solution
with a concentration ≥ 1.5 × 1010 pfu/mL (EB1.ST11), ≥ 1.3 × 109 pfu/mL (EB1.ST27), ≥ 1.6 × 109 pfu/mL
(STA1.ST29) was added when an OD600 of 0.3 was reached. The OD600 was measured at half-hourly intervals
until a decrease could be seen. Chloroform was added at 1 % and the solution was centrifuged (10,000× g for
20 min at room temperature) before supernatant was removed and sterile filtered (using a filter with a pore
size of 0.45 µm, Minisart®NML Plus/NY Plus, Sartorius, Göttingen, Germany). The plaque forming units per
milliliter (pfu/mL) were determined by using a double-layer agar technique modified to the one described
by Sambrook and Russel (Sambrook and Russel 2001). Briefly, 100 µL of the phage serial dilution (Ringer’s
solution; Merck KGaA, Darmstadt, Germany) was added to 100 µL overnight culture of the respective
S. aureus propagation strain and incubated for 5 min at room temperature. After addition of 5 mL top agar,
the assays were mixed by a Vortex Mixer (Vortex Genie®2; Scientific Industries, Bohemia, NY, USA) and
poured onto a petri dish (Ø94 × 16 mm) prepared with 10 mL LB—bottom agar. The inverted plates were
incubated for 18 h at 37 ◦C until the plaque forming units per milliliter (pfu/mL) were determined. The phage
solution was stored in the dark at + 6 ◦C until further investigation.
2.5. Antimicrobial Activity of a Phage Mixture and a Lactic Acid Bacterium in Milk
With regard to a future use in the therapy of S. aureus mastitis in dairy cows, we investigated the
antimicrobial activity of a phage mixture (PM) and a lactic acid bacterium in milk for an approximation
to in vivo conditions. The antimicrobial activity was examined for a single in comparison to a combined
use of the PM (STA1.ST29, EB1.ST11 and EB1.ST27) and the Lb. plantarum strain 118/37 (LAB) against
two S. aureus isolates from mastitis cases, respectively, and was determined by the reduction of the
S. aureus germ density [cfu/mL]. Baird–Parker agar plates were used to prevent contamination by the
lactic acid bacterium, representing a selective culture medium for the isolation of coagulase-positive
Staphylococcus species. The S. aureus isolates 7142 and 10614 were tested for their typical growth
(black colonies surrounded by a clear zone) on Baird–Parker agar before trial. Commercial ultra-high
temperature (UHT) milk was used to achieve high reproducibility and to prevent contamination by the
natural milk microflora. The milk was tested for absence of S. aureus and antibiotic residues by direct
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plating and a Brilliant Black Reduction Test (Delvotest®BR Brilliant, DSM; MILKU Tierhygiene GmbH,
Bovenden, Germany) prior to examination.
TheUHTmilkwas inoculatedwithS.aureus isolates7142or10614respectivelyatanaverageconcentration
of 1.3 × 105 cfu/mL. Depending on the approach a) the PM at a concentration of 1.3 × 109 pfu/mL, b) the LAB
(Lb. plantarum 118/37) at a concentration of 6.6 × 106 cfu/mL or c) a combination of PM and LAB was added,
resulting in a total amount of 7 mL for each approach. Previous examinations [52] have shown the best
reduction ability for the concentrations of S. aureus isolates (7142; 10614) and PM, which were also used in the
present trials. For the application of S. aureus and LAB, a ratio of 1:10 was used according to the findings of
previous studies [53,54].
The pH value was constantly neutralized to prevent germ reduction solely due to acid formation
by the LAB and in order to investigate the effect of other products such as antimicrobial peptides
produced by the LAB. NaOH (1 mol/L) was used to achieve a constant pH value between 6.0 and 7.5.
A fourth approach was solely used to determine the pH values and the amount of NaOH to be added.
Samples were taken after 30 min, after 12 h and after 24 h of incubation at 37 ◦C under aerobic
conditions. Serial dilutions (RINGER, Merck, Darmstadt, Germany) were examined for their S. aureus
germ density by using the spatula method with 100 µL sample material on Baird–Parker agar plates with
addition of egg yolk tellurite (Baird-Parker-Agar, Basis, ROTH; egg yolk tellurite, ROTH) according to
DIN EN ISO 6888-1. The 24 h incubation period was chosen according to common growth characteristics
of LAB in milk and to investigate a possible long-term effect of the LAB on S. aureus [55,56]. To obtain
statistically relevant data, the trial was carried out in triplicate including controls without phages and LAB
(solely S. aureus isolate 7142 or 10,614) and negative controls (UHT milk without additives; solely LAB).
2.6. Statistical Analysis
Three measurements were collected for each data point. A statistical calculation was performed
to determine the influence of the PM, the LAB and their combination on the reduction of the S. aureus
germ density in UHT milk. The values of the S. aureus germ density (cfu/mL) were log transformed
(log10) and one was added to approximate normal distribution. The data were analyzed by ANOVA
using SPSS 25.0 (IBM SPSS 25.0.0.0., Armonk, NY, USA). p values < 0.05 were considered significant.
3. Results
Antimicrobial Activity of a Phage Mixture and a Lactic Acid Bacterium in Milk
The combination of a phage mixture and a lactic acid bacterium as well as their solitary use were
investigated in UHT milk for their antimicrobial activity against S. aureus isolates 7142 and 10614 (initial
concentration of 1.3 × 105 cfu/mL), respectively (Figure 1). Samples were taken after 30 min, 12 h and
after 24 h. The germ density was calculated as cfu/mL and is given as a logarithm of the common mean
values of the two S. aureus isolates [log10 cfu/mL] used for inoculation in the different approaches, as the
statistical calculation showed no significant difference between the two isolates (p > 0.05).
The control without phages and LAB showed an average increase of 3.3 log units in S. aureus germ
density for incubation at 37 ◦C to an average value of 8.5 log cfu/mL (SEM 5.25 log cfu/mL ± 0.15 SEM)
after 12 h. After 24 h of incubation, an average germ density of 6.7 log cfu/mL (SEM 5.25 log cfu/mL
± 0.15 SEM) of S. aureus was observed.
The sole addition of PM resulted in a reduction (p < 0.05) compared to the initial germ
density (5.1 log cfu/mL) by an average of 1.9 log units reduction to a value of 3.2 log cfu/mL (SEM
5.25 log cfu/mL ± 0.15 SEM) after 30 min, a reduction by 5.1 log units to a value of 0.0 log cfu/mL
(SEM 5.25 log cfu/mL ± 0.15 SEM) after 12 h and a reduction by averagely 4.2 log units to a value
of 0.9 log cfu/mL (SEM 5.25 log cfu/mL ± 0.15 SEM) after 24 h of incubation at 37 ◦C (Table 2).
Compared to the control without phages and LAB at the same time, the reduction of the S. aureus
germ density (p < 0.05) was 1.9 log units (30 min), 8.5 log units (12 h) and 5.8 log units (24 h).
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Figure 1. S. aureus germ density for the application of a phage mixture, a lactic acid bacterium and
their combination. The S. aureus germ density [log10 cfu/mL] for 100 µL sample material is given with
standard errors. The common mean values of the two S. aureus isolates 7142 and 10614 are given (SEM
5.25 log cfu/mL ± 0.15 SEM) as the statistical calculation showed no significant difference between the
two S. aureus isolates (p > 0.05). * Time of incubation at 37 ◦C in ultra-high temperature (UHT) milk.
PM = phage mixture (STA1.ST29; EB1.ST11; EB1.ST27) (p < 0.05); LAB = lactic acid bacterium (118/37,
Lb. plantarum) (p > 0.05); PM + LAB = combined application of the phage mixture and the lactic acid
bacterium (p > 0.05).
Table 2. Reduction of S. aureus germ density in log10 units.
Time * PM PM + LAB LAB
A B A B A B
30 min 1.9 1.9 2.0 2.0 0 0
12 h 5.1 8.5 3.9 7.3 + 3.3 0.1
24 h 4.2 5.8 5.1 6.7 + 0.1 1.5
A: compared to the initial value (5.1 log cfu/mL). B: compared to the control without phages and LAB at the same
time. * Time of incubation at 37 ◦C in ultra-high temperature (UHT) milk. PM = phage mixture (STA1.ST29;
EB1.ST11; EB1.ST27) (p < 0.05); LAB = lactic acid bacterium (Lb. plantarum 118/37) (p > 0.05); PM+LAB = combined
application of the phage mixture and lactic acid bacterium (p > 0.05); + = increase in germ density. The common
mean values for the reduction of the two S. aureus isolates 7142 and 10614 are given as the statistical calculation
showed no significant difference between the two S. aureus isolates (p > 0.05).
The addition of the LAB alone did not lead to a reduction of the microbial density compared to
the initial value for a 24 h incubation period, but to an increase by 3.3 log units (12 h) to a value of
8.4 log cfu/mL (SEM 5.25 log cfu/mL ± 0.15 SEM) and an increase by 0.1 log units (24 h) to a value of
5.2 log cfu/mL (SEM 5.25 log cfu/mL ± 0.15 SEM). Nevertheless, a reduction by <1 log unit after 12 h
and by averagely 1.5 log units was shown compared to the control without phages and LAB after 24 h
(p > 0.05).
The combined application of PM and LAB resulted in a reduction of the initial germ density (p > 0.05)
by an average of 2.0 log units (30 min) to a value of 3.1 log cfu/mL (SEM 5.25 log cfu/mL ± 0.15 SEM),
by 3.9 log units (12 h) to a value of 1.2 log cfu/mL (SEM 5.25 log cfu/mL ± 0.15 SEM) and by 5.1 log units
(24 h) to a value of 0.0 log cfu/mL (SEM 5.25 log cfu/mL ± 0.15 SEM). Compared to the control without
phages and LAB at the same time, the combined application led to a reduction (p > 0.05) by 2.0 log units
(30 min), 7.3 log units (12 h) and 6.7 log units (24 h).
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In conclusion, it can be said that the application of PM led to a considerable reduction of the
bacterial density over a period of 24 h in contrast to the sole application of LAB. The statistical
calculation showed significance for the use of PM (p < 0.05), but no significance for the application of
the LAB or the combination of both (p > 0.05). Thus, it can be concluded that the addition of LAB had
no additional effect on the reduction of the S. aureus germ density for an incubation period of 24 h.
4. Discussion
S. aureus strains possess certain pathogenicity factors that hamper antibiotic treatment and lead to
insufficient bacteriological cure rates during lactation [7,15]. Research into alternatives for the treatment
of S. aureus mastitis is therefore an important component in improving cure rates, reducing antibiotic
consumption and thus reducing the risk of developing bacterial resistance. Lytic phages and probiotic
lactic acid bacteria are regarded as alternative approaches in the therapy of bacterial infections.
For this reason, we investigated the combination of a three-component lytic bacteriophage mixture
of sequenced Myo- and Podoviridae and a wild-type Lb. plantarum strain against S. aureus isolates from
mastitis cases. Since obligatory lytic phages usually lead to a rapid reduction of pathogens, while
lactic acid bacteria proliferate more slowly, but can establish themselves in the target tissue for longer,
this combination was assumed to have an advantage for the treatment of S. aureus mastitis compared
to use alone. Thus, an incubation period of 24 h was chosen considering the slower growth and the
delayed production of antimicrobial peptides by the LAB. The present in vitro examinations were
conducted with regard to a combined use in mastitis therapy. The S. aureus isolates used for inoculation
were already investigated in a previous study and the PM also used in the present study was able to
significantly reduce the S. aureus isolates in pasteurized and raw milk [52].
Bacteriophages are viruses that exclusively target prokaryotic cells. Obligately lytic phages in
particular are able to proliferate inside and lyse the host cell within a short time. Phages commonly
show very host-specific targeting, which leads to protection of the apathogenic flora in the target tissue
when administered in vivo [21]. Several examinations in animal models have already demonstrated
that the use of bacteriophages in vivo leads to a significant pathogen reduction without adverse effects
on the treated animals [17,18,20].
Similar to any antibacterial agent, bacterial resistance can develop against phages. However,
the possibility for a comparatively rapid isolation of new phages, the use of obligately lytic and sequenced
phages with a lack of lysogenic potential, the usage of several phages in a mixture and finally the opportunity
for a combined use of phages and antimicrobial agents reduce the risk for resistance development and
represent advantages over common antibiotics [23,25,57,58]. In the present study, we used a mixture of
obligately lytic, sequenced phages to fulfil functional and safety requirements. The phages of the mixture
were already investigated in a previous study, resulting in a broad host spectrum against S. aureus isolates
from mastitis cases [52].
Lactic acid bacteria also possess the ability to inhibit the growth of pathogens by the colonization
of epithelia, the competition for nutrients and the production of antimicrobial active substances [30–32].
Lb. plantarum strains are known for their probiotic properties partly due to their production of
a bacteriocin called plantaricin [44–46]. The literature describes general properties of lactic acid bacteria
intended to be used as probiotics. These include a proven antagonistic activity against pathogens,
the adhesion to and the persistence on epithelia, as well as the survival and a maintained functionality
in the target tissue [34]. In addition, the modulation of the host’s immune response represents
an important probiotic property [34,59,60]. Safety aspects include the absence of resistance-coding
genes and a general susceptibility to antibiotics in case of treating immunosuppressed patients [34].
The LAB 118/37 used in the present study was isolated from milk and was already examined by
Diepers et al. (2017) [47]. This Lb. plantarum strain was selected for the present examinations based on
its properties, such as a proven antimicrobial activity against S. aureus, the possibility of using milk as
a nutritional substrate and the ability to adhere to mammary gland canal epithelial cells in vitro [47].
In addition, its lack of resistance-coding genes fulfills an important safety requirement [34,47].
Vet. Sci. 2020, 7, 31 8 of 13
In the present study, we investigated the antimicrobial activity of a single and a combined use of the
PM and the LAB against S. aureus isolates in UHT milk. The S. aureus isolates originated from quarter
foremilk samples of mastitis cases and thus present typical mastitis causing pathogens. The antimicrobial
activity was evaluated for the reduction of the S. aureus germ density in relation to the initial germ density
(t0h), and in relation to the values of the control culture without phages after the same incubation period.
The statistical calculation showed significance only for the use of PM. The evaluation of the results has
already shown an effect on the germ density at the beginning of the experiment (t30min). Both the PM
(p < 0.05) and the combination of PM and LAB (p > 0.05) led to a reduction of the S. aureus germ density
in UHT milk after 30 min compared to the initial value, which increased to an average reduction by
5.1 log units (PM) (p < 0.05) and 3.9 log units (PM + LAB) (p > 0.05) after 12 h. Compared to the initial
values, the reduction ability decreased slightly after 24 h when using PM alone (reduction by 4.2 log
units; p < 0.05), but increased further when combining PM and LAB after 24 h incubation (reduction by
5.1 log units; p > 0.05). The highest reduction compared to the initial values was thus shown after 12 h
for the use of PM (p < 0.05) and after 24 h for the combination of PM and LAB (p > 0.05).
A constant reduction was also shown in comparison to the controls without phages, with the
highest reduction by 8.5 log units for PM (p < 0.05) and by 7.3 log units for the combination (p > 0.05)
after 12 h. The use of the LAB alone led to no reduction when compared to the initial values for an
incubation period of 24 h, but to a slight increase in germ density. Nevertheless, compared to the
control culture without phages, the LAB led to a reduction of the S. aureus germ density by 1.5 log
units after 24 h (p > 0.05).
It can therefore be said that for an incubation period of 24 h, only the use of PM led to a significant
reduction in germ density (p < 0.05). The combination of PM and LAB was more successful than the
use of LAB alone in terms of antimicrobial activity against S. aureus in UHT milk, but both did not
show significance (p > 0.05).
The results of the present investigations are partly comparable to the results of Woo and Ahn
(2014) for their examination of a combined use of phage SA11 and a Lactobacillus (Lb.) rhamnosus strain
against Staphylococcus aureus for modeled intestinal conditions in vitro at different pH values [61].
Phage SA11 inhibited the growth of antibiotic-sensitive and -resistant S. aureus strains if compared
to the control cultures after 10 h, whereas the single use of Lb. rhamnosus led to an inhibition of the
germ density first after 20 h in comparison to the corresponding values of the control culture without
phages. Thus, the authors suggested that phage lytic activity was predominant after 10 h of incubation
and the antimicrobial activity of LAB after 20 h. The authors described the highest reduction ability for
a combined application of phage and LAB after 10 h and 20 h [61].
In our study, the use of the PM resulted in a reduction ability already after 30 min (p < 0.05). It has
to be pointed out that the reduction was shown at each sampling time compared to the initial values as
well as to the control culture. The combination of PM and LAB also led to a reduction after 30 min,
after 12 h and after 24 h, but without significance (p > 0.05). From this, it can be concluded that the
addition of LAB did not show an increase or synergism for an incubation period of 24 h. The sole use
of the LAB in the present study led to a reduction only compared to the values of the control culture
without phages first after 24 h of incubation (p > 0.05), which is comparable to the results of Woo and
Ahn (2014) and will be related to the fact that the proliferation, the synthesis of antimicrobial peptides
and consequently the antimicrobial activity of LAB requires more time than that of obligately lytic
phages. This could also be a possible reason explaining why the combination with LAB and the use of
LAB alone did not lead to a significant result (p > 0.05). As with all microorganisms, there is a lag
phase, where bacteria adapt to growth conditions, and so the effect of the LAB probably started when
the present measurements were finished after 24 h. Therefore, an extension of the observation time
would be necessary. A further in vivo trial could be used to investigate whether the LAB, by being
established in the udder, could be more effective and whether a prolonged incubation period in vivo
may potentially lead to a significant effect of the LAB against S. aureus. In any case, our results show
that there are no negative interferences between the PM and the LAB which would have led to a lower
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reduction in the combined application, underlining the possibility of a combined use in further trials.
In this combination, lytic phages could thus achieve a short-term effect, whereas the LAB could offer
the advantage of a long-term effect by establishing itself in the target tissue. At this point, further
examinations are necessary to investigate this context more detailed in vivo.
Further, it is possible that incubation under anaerobic conditions would have had an influence on
the antimicrobial activity of the Lb. plantarum strain. However, the present in vitro investigations were
conducted against the background of in vivo use in the treatment of mastitis cases and as LAB represent
anaerobic but aerotolerant microorganisms, the approaches were incubated under aerobic conditions.
Although the resistance situation of antibiotics for mastitis therapy in Germany can still be
described as moderate, the isolation of resistant S. aureus strains from mastitis cases and tank milk has
been published [9,62,63]. Since the development of antibiotic resistance follows a natural process and
any application and in particular the improper administration of antibacterial agents can lead to the
development of resistance in bacteria, alternative solutions for the treatment of bacterial infections
are needed [3,5]. The use of probiotic lactic acid bacteria as well as phages in therapy represents such
alternative approaches and offers several advantages. These include, among others, the protection
of the apathogenic flora when using phages [21], the modulation of the immune system by LAB as
a probiotic property [34] as well as a self-limitation of phages at low S. aureus concentrations [17] and,
in contrast, a possible long-term effect of LAB by establishing themselves in the udder. There are already
investigations on a combined use of phages and probiotics against different pathogens [61,64,65].
Dini et al. (2016) demonstrated pathogen reduction in the treatment of in vitro EHEC infection using the
phage CA933P and a probiotic mixture, with a diminishing cytotoxic effect. The authors additionally
demonstrated freeze drying as a method of storage with no significant reduction in concentration of the
two components [66]. We determined a storability of the phages used in the present study for a period
of six month at +6 ◦C without a substantial loss of efficacy (< 1 log unit), determined for pfu/mL in
periodically performed plaque assays of the phage solution after propagation and sterile filtration.
This storage stability represents an important factor with regard to its therapeutic use [67]. Another
study investigated the use of phage P22 and a mixture of four bacteriocin-producing Lactobacilli for the
treatment of Salmonella infection in chicken, resulting in the total elimination of intestinal Salmonella
after 48 h [64]. Accordingly, the investigation of phages and LAB against pathogens is not new but,
to our knowledge, the present study is the first examination of a combined use with regard to bovine
mastitis therapy.
Further studies are needed to investigate the efficacy of a combined application of phages and
LAB for the treatment of S. aureus mastitis more detailed in vivo. For this case, the combination of
the phage mixture and the LAB 118/37 could be applied into the teat canal of healthy udders for
a tolerability assessment, followed by the investigation of the BC rates of an intramammary treatment
in comparison to treatment with common antibiotic agents. Further examinations could also deal with
a prophylactic use in the cleaning of milking equipment. D’Accolti et al. (2018) already demonstrated
that a combination of phages (Staphylococcal phage and Pyophage) and the probiotic PCHS detergent
including spores of three Bacillus species led to decontamination of hard surfaces in the hospital
environment (hospital-acquired pathogens, e.g., antibiotic-sensitive and -resistant S. aureus) [65].
The authors also noted that the probiotic detergent not only had a positive effect on the maintenance
of phage efficacy, but also led to an increased activity compared to the suspension in PBS. Thus,
they suggested the phage–probiotic combination for use as a routine disinfectant [65]. In the present
study, the LAB had no adverse effect on the activity of the phages when used in combination and
an extended incubation period in further investigations could possibly lead to a significant influence
on the S. aureus germ density.
It is a fact that any use of antibiotics promotes the development of bacterial resistance and some
bacterial infections, such as S. aureus infections, whether in animals or humans, may not respond
adequately to antibiotics [5]. These problems make it necessary to research alternatives for the therapy
of bacterial infections. Against the background of a limited number of studies on a combination of
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phages and LAB and no prior investigation into mastitis therapy, the present study provides a basis for
future investigations. Nevertheless, further in vivo studies are necessary to find adequate application
doses and intervals as in vitro investigations are not fully able to reproduce in vivo conditions due to
the complex anatomical and physiological conditions of the bovine udder.
5. Conclusions
The antimicrobial activity of a single application as well as the combination of a Lb. plantarum strain
with proven antimicrobial properties and a lytic three-component phage mixture was investigated
in milk against S. aureus isolates from bovine mastitis. The single application of the phage mixture
showed the most efficient reduction of S. aureus germ density after 12 h (p < 0.05). The combination of
the phage mixture and the lactic acid bacterium showed the highest antimicrobial activity after 24 h
(p > 0.05). Statistical calculations showed that only the phage mixture had a significant effect on the
S. aureus germ density for an incubation period of 24 h.
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